FDA Cleared Home Test for COVID, Flu, and RSV

The newly authorized diagnostic tool uses a single swab to detect four viral pathogens at once.

Updated on Sept. 22, 2026 in Diseases — General

Isometric editorial illustration of a medical nasal swab and collection vial, representing a new multi-pathogen home diagnostic test. — The FDA has granted clearance for a home diagnostic test that screens for COVID-19, influenza, and RSV using a single nasal swab. AI Illustration. Upload story photo >

Live Poll

Do you feel having home diagnostic tests for multiple viruses makes you better prepared for illness?

The FDA has granted clearance for a home diagnostic test capable of detecting COVID-19, influenza, and RSV from a single swab. This development offers a more efficient way to differentiate between respiratory illnesses with overlapping symptoms.

Why it matters

Distinguishing between these respiratory viruses is challenging because their symptoms frequently overlap in infected patients. This new test provides a clearer path for diagnosis without requiring multiple separate clinical visits.

The device demonstrated a sensitivity rate of 92% to 94% across a study of 1,263 symptomatic individuals. This performance significantly exceeds the 51% to 67.5% sensitivity range typically associated with older rapid influenza tests.

The players

FDA

The Food and Drug Administration is the federal agency responsible for regulating medical devices and diagnostic tests in the United States.

The details

The diagnostic device streamlines the testing process by screening for four distinct viral pathogens using only one nasal swab. Researchers validated these results through a study conducted across 10 U.S. cities, addressing long-standing difficulties in distinguishing between respiratory infections.

The 2009 H1N1 pandemic highlighted the limitations of previous rapid test technologies.
A 2018 review examined the sensitivity limitations of then-current rapid influenza tests.
The clearance study for the device took place between October 2024 and April 2025.

Health Landscape

This diagnostic advancement represents a major leap in accuracy when measured against the 17.8% sensitivity rate recorded during the 2009 H1N1 pandemic. It reflects a broader evolution in medical testing, moving from low-sensitivity legacy tools toward highly accurate multiplex platforms.

This clearance provides patients with a reliable method to identify their specific respiratory illness from home, potentially reducing unnecessary healthcare visits. Users will likely benefit from faster access to appropriate treatments based on more accurate early identification.

The takeaway

Advancements in multiplex diagnostic testing are narrowing the gap between professional laboratory accuracy and home-based convenience. Patients should look for authorized testing options that provide comprehensive coverage for multiple viral pathogens.